Extremely low frequency (ELF) pulsed-gradient magnetic fields inhibit malignant tumour growth
at different biological levels
Extremely low frequency (ELF) pulsed-gradient magnetic field (with the maximum intensity of
0.6-2.0 T, gradient of 10-100 T.M(-1), pulse width of 20-200 ms and frequency of 0.16-1.34 Hz
treatment of mice can inhibit murine malignant tumour growth, as seen from analyses at different
hierarchical levels, from organism, organ, to tissue, and down to cell and macromolecules. Such
magnetic fields induce apoptosis of cancer cells, and arrest neoangiogenesis, preventing a supply
developing to the tumour. The growth of sarcomas might be amenable to such new method of
- Author: Zhang, X. and Zhang, H. and Zheng, C. and Li, C. and Xiong,
- Year: 2002
- Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12127939
- Comment:Zhang, Xinchen Zhang, Husheng Zheng, Congyi Li, Chaoyang Zhang,
Xinsong Xiong, Wei Research Support, Non-U.S. Gov't England Cell biology international Cell
Biol Int. 2002;26(7):599-603.
- Address: Biomedical Physics Unit, Department of Physics, Wuhan University,
Wuhan, 430072, China.
- Booktitle: Cell Biol Int
[Effects of steep pulsed electric fields on cancer cell proliferation and cell cycle]
To assess study the cytocidal and inhibitory effects of steep pulsed electric fields (SPEFs) on
ovarian cancer cell line SKOV3, the cancer cell suspension was treated by SPEFs with different
parameters (frequency, pulse duration, peak value of voltage). Viability rate and growth curves of
two test groups (high dosage and low dosage of SPEFs) and one control group were also measured. The
DNA contents and cell cycle were analyzed by flow cytometry (FCM). Different dosing levels of SPEFs
exerted obviously different effects on cancer cell viability. With the enhancement of each pulse
parameter, the viability rate was promoted and the inhibitory effect on the proliferation of
treated cells was more evident. The cells exposed to SPEFs grew slower than the control. The ratio
of S+G2/M phase cells was decreased, which restrained the DNA synthesis and division, but the ratio
of G0/G1 phase cells was increased in the treated groups. It was also indicated that the SPEFs
blocked the cell transition from G0/G1 phase to S+G2/M phase. There was a significant difference in
cell cycle between treated group and control group (P<0.01). Lethal effects of SPEFs were
represented by inhibiting the cancer cell proliferation at the cell level and by influencing the
cell cycle at the DNA level.
- Author: Yao, C. and Sun, C. and Mi, Y. and Xiong, L. and Hu, L. and Hu,
- Year: 2004
- Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15357428
- Comment:Yao, Chenguo Sun, Caixin Mi, Yan Xiong, Lan Hu, Lina Hu, Ya
English Abstract Research Support, Non-U.S. Gov't
- Address: Key Lab of High Voltage Engineering and Electrical New
Technology, Ministry of Education, Chongqing University, Chongqing 400044, China.
- Booktitle: Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
Effects of pulsed magnetic stimulation on tumor development and immune functions in mice
We investigated the effects of pulsed magnetic stimulation on tumor development processes and
immune functions in mice. A circular coil (inner diameter = 15 mm, outer diameter = 75 mm) was used
in the experiments. Stimulus conditions were pulse width = 238 micros, peak magnetic field = 0.25 T
(at the center of the coil), frequency = 25 pulses/s, 1,000 pulses/sample/day and magnetically
induced eddy currents in mice = 0.79-1.54 A/m(2). In an animal study, B16-BL6 melanoma model mice
were exposed to the pulsed magnetic stimulation for 16 days from the day of injection of cancer
cells. A tumor growth study revealed a significant tumor weight decrease in the stimulated group
(54% of the sham group). In a cellular study, B16-BL6 cells were also exposed to the magnetic field
(1,000 pulses/sample, and eddy currents at the bottom of the dish = 2.36-2.90 A/m(2)); however, the
magnetically induced eddy currents had no effect on cell viabilities. Cytokine production in mouse
spleens was measured to analyze the immunomodulatory effect after the pulsed magnetic stimulation.
tumor necrosis factor (TNF-alpha) production in mouse spleens was significantly activated after the
exposure of the stimulus condition described above. These results showed the first evidence of the
anti-tumor effect and immunomodulatory effects brought about by the application of repetitive
magnetic stimulation and also suggested the possible relationship between anti-tumor effects and
the increase of TNF-alpha levels caused by pulsed magnetic stimulation.
- Author: Yamaguchi, S. and Ogiue-Ikeda, M. and Sekino, M. and Ueno, S.
- Year: 2006
- Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16304693
- Comment:Yamaguchi, Sachiko Ogiue-Ikeda, Mari Sekino, Masaki Ueno, Shoogo
Research Support, Non-U.S. Gov't United States Bioelectromagnetics Bioelectromagnetics. 2006
- Address: Department of Biomedical Engineering, Graduate School of
Medicine, University of Tokyo, Japan. firstname.lastname@example.org
- Booktitle: Bioelectromagnetics
Therapeutic electromagnetic field effects on angiogenesis and tumor growth
BACKGROUND: A new approach to cancer therapy based on the application of therapeutic
electromagnetic fields (TEMF) has been developed by EMF Therapeutics, Inc., Chattanooga, TN, USA.
This study was designed to assess the effect of TEMF on tumor vascularization and growth of murine
16/C mammary adenocarcinoma cells in C3H/HeJ mice. MATERIALS AND METHODS: Implanted tumors were
allowed to grow for seven days until the tumor volume reached 100 mm3 before treatment was started.
Mice (20 per control, 10 per EMF exposed group) received treatment (10 minutes per day with 0, 10
mT, 15 mT or 20 mT) with a 120 pulses per second pulsating magnetic field. Tumor growth was
assessed throughout the treatment period. The extent of tumor vascularization was evaluated by
immunohistochemical staining for CD31. RESULTS: Exposure to TEMF significantly reduced tumor
growth, significantly reduced the percentage of area stained for CD31 indicating a reduction in the
extent of vascularization and there was a concomitant increase in the extent of tumor necrosis.
CONCLUSION: A novel TEMF treatment safely reduced growth and vascularization of implanted breast
cancers in mice. IMPLICATION: TEMF may prove a useful adjuvant to increase the therapeutic index of
conventional cancer therapy.
- Author: Williams, C. D. and Markov, M. S. and Hardman, W. E. and Cameron,
- Year: 2001
- Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11911264
- Comment:Williams, C D Markov, M S Hardman, W E Cameron, I L Greece
Anticancer research Anticancer Res. 2001 Nov-Dec;21(6A):3887-91.
- Address: EMF Therapeutics, Inc., Chattanooga, TN 37405, USA.
- Booktitle: Anticancer Res
Please note that these pages are for general information purposes, to give you an idea of the scope of
PEMF, how it works, what research
studies show about its general effects, and the wide range of health issues that have been
helped by it. These studies, and
explanations should not be interpreted as proof that anyone other
than the study participants would receive the same reported benefits. Rather it is provided as a source of inspiration to you in how it might
help you improve your own health. Our approach is that if your body has the optimal conditions for good
health, it will be better equipped to deal with any health challenges it may face, now or in the
Some PEMF systems may be used in a
medical setting, and our products are listed and regulated by the US Food and Drug Administration (FDA).
However, our products are intended for use at home in promoting general wellness and helping the
body to stay healthy. They are therefore not intended for use in the
diagnosis of specific diseases or medical conditions, or in their cure, mitigation, treatment or
prevention. The information
contained in these pages is not in any way intended to help you
diagnose a medical condition, or to replace the advice and/or services of a physician or other health care
If you suspect that you have a medical condition, you should first seek a diagnosis from a doctor,
and, if you decide to use PEMF, work under their
supervision in assessing the progress of the condition and the dosage of
any drugs you may be taking.The opinions and information on this website have not been
evaluated by the FDA or the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). They should not
be considered complete in terms of the physical conditions discussed, or construed as healthcare
While we endeavour to keep the information in these
pages up to date and correct, we make no representations or warranties of any kind, express or implied, about the
completeness, accuracy, reliability, suitability or availability with respect to the website or the information,
products, services, or related graphics contained on the website for any purpose. Any reliance you place on such
information is therefore strictly at your own risk.